Furkat Abdulakhatovich Yusupov

Furkat Abdulakhatovich Yusupov

Auto-generated profile, based on publicly available information

Furkat Abdulakhatovich Yusupov

Osh State University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2025 in Clinical Medicine (Russian Journal)
Verified
Journal Article
Closed access
PDF file
FYF. A. Yusupov
F. A. Yusupov
IYI. T. Ydyrysov
I. T. Ydyrysov
MAM. Sh. Abdykadyrov
M. Sh. Abdykadyrov
TYT. F. Yusupova
T. F. Yusupova
Parkinson’s disease (PD) affects men and women differently, creating unique challenges and approaches in its treatment. Men are twice as likely to develop PD as women, but women experience higher mortality rates and faster disease progression. Moreover, motor and non-motor symptoms, response to treatment, and risk factors differ between men and women. These differences support the hypothesis that the disease’s pathogenesis may involve different mechanisms in male and female patients, or the same mechanisms manifesting differently. This review summarizes current knowledge on gender differences in the clinical manifestations of PD, risk factors, treatment response, and the disease’s pathophysiological mechanisms. Understanding how the pathology differently affects men and women can aid in the development of individualized interventions and innovative programs to meet the varied needs of patients of both sexes, thereby improving the quality of care.

5 August 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
FYF.A. Yusupov
F.A. Yusupov
AIAkmal Iuldashev
Akmal Iuldashev
MAM.SH. Abdykadyrov
M.SH. Abdykadyrov
TYT.F. Yusupova
T.F. Yusupova
Numerous studies showed an association between Parkinson’s disease and low uric acid levels. Low uric acid levels are associated with an increased risk of Parkinson’s disease, its progression, and the severity of symptoms. Although the biological mechanisms for this association have not yet been established, it is suggested that uric acid acts as an antioxidant, reducing oxidative stress and protecting dopaminergic neurons. However, some recent studies question this hypothesis. The article discusses the biological properties of uric acid, its relationship to Parkinson’s disease, and the possibility of reverse causation, where the disease causes a decrease in uric acid levels. The presented data support further research to understand these relationships more deeply, possibly leading to new disease treatment approaches.

14 December 2023 in Clinical Medicine (Russian Journal)
Verified
Journal Article
Closed access
PDF file
IMI. T. Murkamilov
I. T. Murkamilov
KAK. A. Aitbaev
K. A. Aitbaev
VFV. V. Fomin
V. V. Fomin
ZMZh. A. Murkamilova
Zh. A. Murkamilova
PAP. A. Astanin
P. A. Astanin
FYF. A. Yusupov
F. A. Yusupov
Essential hypertension (EH) is the most common cardiovascular disease and the leading cause of chronic kidney disease (CKD) worldwide. The aim of the study was to investigate the frequency and nature of kidney damage in hypertension. 189 patients (69 men and 120 women) with hypertension (stages I, II, and III) aged 43 years and older were examined. The average age of the patients was 61.2 ± 8.7 years. Clinical and biochemical tests were conducted on all patients, including red blood cell indices, C-reactive protein (CRP), lipid profile, fibrinogen, electrolytes, glucose, uric acid, creatinine, and cystatin C. The duration of hypertension was also recorded for each patient. Kidney function was assessed using serum creatinine (CKD-EPI) and cystatin C (F. Houcke). Patients were categorized according to the degree of decrease in glomerular filtration rate (GFR) based on the recommendations of the Russian Nephrology Society. Patients with kidney damage were divided into two groups: Group 1 consisted of patients with hypertension without signs of CKD (GFR calculated by cystatin C ≥ 60 ml/min), while Group 2 consisted of patients with hypertension complicated by CKD. The results showed that hypertension was accompanied by target organ damage in 70.8% of cases. The prevalence of CKD among patients with hypertension was 28.5%. Proteinuria was mainly detected in patients with renal insufficiency. The frequency of GFR categories according to CKD-EPI and F. Houcke formulas was as follows: G1 — 54.4% and 13.7% (p < 0.05); G2 — 35.9% and 57.6% (p < 0.05); G3a — 5.2% and 19.5% (p < 0.05); G3b — 3.1% and 5.2% (p < 0.05); G4 — 0.5% and 3.1% (p < 0.05) and G5 — 0.5% and 0.5%, respectively. There was a strong correlation between GFR and serum creatinine (r = –0.439; p < 0.05) and cystatin C (r = –0.866; p < 0.0001). Patients in Group 2 (hypertension with kidney damage) had significantly higher levels of CRP, low-density lipoprotein cholesterol, cystatin C, and longer duration of hypertension, but lower levels of total calcium than patients in Group 1. In conclusion, CKD was present in 28.5% of patients with hypertension, and proteinuria was mainly detected in patients with renal insufficiency. Serum cystatin C levels most accurately reflect kidney filtration function.

15 September 2021 in Bulletin of Science and Practice
Verified
Journal Article
Open access
FYF. Yusupov
F. Yusupov
AIAkmal Iuldashev
Akmal Iuldashev
The proportion of neurodegenerative diseases among all neurological disorders is growing year after year. This is explained by the duration of the latency period and the manifestation of signs after the death of about 40–60% of neurons. According to WHO forecasts, neurodegenerative diseases will be the biggest problem in the healthcare system of the XXI century. Among them, the most acute can be considered Alzheimer’s and Parkinson’s diseases. Specific biomarkers of neurodegenerative diseases (diseases: Alzheimer’s; Parkinson’s; Huntington’s) are discussed. Currently, the highest priority in neurology is the identification of specific biomarkers in the blood serum for each nosology. In medicine, less invasive, atraumatic methods are always encouraged, therefore, the detection of biomarkers in the blood has advantages over the detection in the cerebrospinal fluid, the production of which is more invasive. The review examines the biomarkers of Alzheimer’s, Parkinson’s and Huntington’s diseases.

14 October 2025 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
FYF. A. Yusupov
F. A. Yusupov
MAM. Sh. Abdykadyrov
M. Sh. Abdykadyrov
Parkinson’s disease is the second most common progressive neurodegenerative disease after Alzheimer’s disease, characterized by selective loss of dopaminergic neurons in the compact part of the substantia nigra. This leads to striatal dopamine deficiency and motor symptoms. Along with this, non-motor disorders, in particular cardiovascular dysfunctions, play a significant role in the pathogenesis of Parkinson’s disease, which have a significant impact on the quality of life of patients.Neurogenic mechanisms include pathological accumulation and aggregation of alpha-synuclein with the formation of Lewy bodies and neurites, detected in both the central and peripheral autonomic nervous systems, including the heart sympathetic innervation. Additionally, non-neurogenic factors (decreased intravascular volume due to dysphagia and inadequate fluid intake, heart failure, and antiparkinsonian-induced hypotension) contribute to orthostatic hypotension and other cardiovascular events, increasing the risk of stroke and other complications.In addition to autonomic and motor manifestations, mental and cognitive impairment is of paramount importance in Parkinson’s disease. Depression, anxiety, and dementia are found in 40-50% of patients, often in the early stages of the disease, and through activation of the sympathoadrenal system, increased cortisol levels, and baroreflex dysfunction can exacerbate arrhythmias, ischemic episodes, and other cardiac events. In addition, decreased motivation and adherence to therapy with mental symptoms further increases the risk of adverse cardiovascular outcomes in this group of patients.

15 July 2024 in Bulletin of Science and Practice
Verified
Journal Article
Closed access
FYF. Yusupov
F. Yusupov
AIAkmal Iuldashev
Akmal Iuldashev
TNT. Nurmatov
T. Nurmatov
The World Health Organization (WHO) has stated that neurodegenerative diseases will be the biggest health problem in the future. Among neurodegenerative diseases, Parkinson’s disease is the second most common after Alzheimer’s disease. Parkinson’s disease (PD) is the most common pathology of a person with movement disorders. Among neurological diseases, it has a high social significance due to the negative effect on the quality of life (early loss of the ability to work, progressive disorders of motor and cognitive skills). With increasing life expectancy, the prevalence of Parkinson’s disease increases. Biological markers of early diagnosis of Parkinson’s disease are being actively studied. The review presents the most clinically significant biological markers for the preclinical diagnosis of Parkinson’s disease. Biomarkers of cerebrospinal fluid, serum biomarkers and biomarkers of other biological fluids in Parkinson's disease are discussed.